注射用盐酸苯达莫司汀单药治疗利妥昔单抗耐药的B细胞惰性淋巴瘤  

Bendamustine hydrochloride in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma

作　　者：闵琦[1] 王华庆[1] 钱正子[1] 张会来[1] 周世勇[1] 邱立华[1] 宋拯[1] 赵静[1] 刘霞[1] 

机构地区：[1]天津医科大学肿瘤医院淋巴瘤科、国家肿瘤临床医学研究中心、天津市肿瘤防治重点实验室,天津市300060

出　　处：《中国肿瘤临床》2014年第19期1239-1243,共5页Chinese Journal of Clinical Oncology

摘　　要：目的:观察注射用盐酸苯达莫司汀单药治疗利妥昔单抗耐药的B细胞惰性淋巴瘤临床疗效及安全性。方法:25例利妥昔单抗治疗失败的B细胞惰性淋巴瘤患者,接受苯达莫司汀单药化疗(120 mg/m2,d1、2,每21天为1个周期),评价其近期疗效、无进展生存期与不良反应。结果:全组25例患者,共计化疗122个周期,中位5个周期。治疗2个周期后均可评价疗效,其中完全缓解(CR/CRu)6例,部分缓解(PR)13例,稳定(SD)3例,进展(PD)3例,总有效率(ORR)为76%,临床受益率(CBR)为88%。截至随访结束,13例患者出现PFS终点事件,中位疗效持续时间(DOR)8个月,中位无进展生存期(PFS)9个月。各亚组间无进展生存期的关系,主要与骨髓受累、血清LDH水平升高有关,差异有统计学意义(P<0.05)。常见不良反应为骨髓抑制、胃肠道反应和感染,2例患者出现皮疹,1例患者用药5个周期后发生胃癌。结论:注射用盐酸苯达莫司汀单药治疗利妥昔单抗耐药的B细胞惰性淋巴瘤可提高疗效,且耐受性良好。Objective：To observe the clinical efficacy and toxicities of bendamustine hydrochloride in patients with rituximab-refractory indolent B-cell non-Hodgkin＇s lymphoma （NHL）. Methods：A total of 25 patients with rituximab-refractory NHL received bendamustine hydrochloride 120 mg/m2 intravenously on days 1 and 2 of the 21-day cycle. The short-term response, progression free survival, and toxicities were evaluated. Results：The total number of chemotherapy of the 25 patients was 122 cycles, and the median number was 5 cycles. All patients could be evaluated for efficacy. Among the patients, 6 had complete remission, 13 had partial remission, 3 had stable disease, and 3 had progression disease. The overall response rate and clinical benefit rate were 76%and 88%, respec-tively. Until the deadline, 13 patients had progression disease. The median duration of response was 8 months, and the median progres-sion-free survival （PFS） was 9.3 months. Subgroup analysis showed that PFS is significantly related to bone marrow involvement and serum LDH level （P〈0.05）. The main adverse effects were myelosuppression, gastrointestinal reactions, and infection. Rash was found in 2 patients, and 1 case of gastric cancer was discovered after 5 cycles of treatment. Conclusion：Bendamustine hydrochloride was effective and tolerable in patients with rituximab-refractory indolent B-cell NHL.

关 键 词：盐酸苯达莫司汀 B细胞惰性淋巴瘤 利妥昔单抗耐药 疗效 安全性 

分 类 号：R733.1[医药卫生—肿瘤]